ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ UNG THƯ BIỂU MÔ TẾ BÀO GAN GIAI ĐOẠN TIẾN TRIỂN BẰNG PHƯƠNG PHÁP TRUYỀN HÓA CHẤT ĐỘNG MẠCH GAN (HAIC)

Abstract

Purpose: To evaluate the initial safety and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular Carcinoma. Materials and methods: Retrospective, prospective study with longitudinal follow-up of 12 patients (patients) diagnosed with HCC from 6/2019 to 9/2022 who were treated with hepatic artery chemotherapy. After 1 month and over 3 months, the patient was re-examined for clinical assessment, tested by a tumor marker and again computed tomography (CT) of the liver with contrast injection. We take image information abouts tumor diameter, tumor contrast enhancement patterns.We assess treatment response according to the standard of response evaluation for solid tumors (mRECIST). Follow up the survival time of patients who have more than 3 months after treatment. Results: 12 patients (10 men, 2 women) with mean age 54.5±14.3 years (from 31 years old to 76 years old), mean tumor diameter 87±35 mm, The median value of AFP tumor marker is 3351 ng/ml. Immediately after implantation, 1 patient had complications of catheter occlusion, 1 patient had an infection at the chamber placement. After the time of intervention, treatment with Low dose FP regimen for 1 month, there were 12 patients re-examined, the level of complete, partial, stable response, progression on mRECIST was 0%, 16.7%, 50%, 33,3%, 1 patient appeared liver failure, stopped treatment. At more than 3 months, there were 8 patients re-examined, the level of complete, partial, stable, and progressive response according to mRECIST was 0%, 25%, 50%, 25%. There’s decrease value of tumor marker after treatment but has not significant. 8 patients with time to follow-up more than 3 months, of which 3 patients are still alive and continue to be treated. Conclusion: Hepatic arterial chemotherapy is an effective and safe treatment, especially for locally invasive advanced HCC.